10032341A game changing service-led innovation in menopause managementClosedInvestment AcceleratorInnovate UKMenopause is a long-term hormone deficiency which will be experienced by every woman. The current management strategies focus on illness not wellness and clinicians are limited by lack of objective and accurate testing options. This leaves women with limited options and treatment plans that are not monitored for efficacy. Agile Life Sciences (ALS) has developed a game changing service which can measure and monitor the effects of hormone changes on the vaginal microbiome - the vaginome. This highly innovative service will provide menopause clinicians with robust data to help guide them in providing the best possible care and treatment plans to peri and post menopausal women. Our project focusses on developing a solution which uses state-of-the-art next generation sequencing technology to analyse urine samples to measure and monitor the bacteria in the vaginome. By monitoring the changes in these bacteria we can identify the menopause phase and the risk of UTIs. By partnering with menopause clinicians, key opinion leaders and end users we will develop a service that is tailored to peri and post menopausal women and enables them to take control of their own health and live a life without limitations. Our at home easy sample collection has been designed to be convenient and allows women to manage their menopause journey with the support of cutting-edge technology. The outcome of the project will be a fully serviceable test for menopause clinicians with a pilot launch to collaborative KOLs within 4 months and the full service launch within 9 months.